Cancer Center Clínica Universidad de Navarra (CCUN)

Centro clínico de la Universidad de Navarra

Foto de Cancer Center Clínica Universidad de Navarra (CCUN)

Foto de West Virginia University

West Virginia University

Morgantown, Estados Unidos

Publicaciones en colaboración con investigadores/as de West Virginia University (6)

2024

AI is a viable alternative to high throughput screening: a 318-target study
Scientific Reports, Vol. 14, Núm. 1
Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)
Scientific Reports

2022

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
European Journal of Haematology, Vol. 108, Núm. 1, pp. 73-83

2021

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
Leukemia and Lymphoma, Vol. 61, Núm. 8, pp. 1850-1859

2018

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalanprednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
Haematologica, Vol. 103, Núm. 9, pp. 1518-1526